Ventfort: Mechanism, Dosing & Research Data

Ventfort is a synthetic tripeptide (Lys-Glu-Asp) developed within the Khavinson bioregulatory peptide paradigm as a vascular tissue bioregulator. It is designed to penetrate endothelial and smooth muscle cell nuclei and modulate gene expression in vascular tissue, with purported effects on vessel tone, endothelial function, and age-related vascular changes. It is used in the Eastern European longevity peptide community as a cardiovascular anti-aging compound.

Mechanism of Action

Khavinson bioregulatory peptide theory: short peptides (2-4 aa) containing charged residues interact with DNA promoter elements via complementary electrostatic interactions, modulating gene transcription in a tissue-specific manner
Proposed endothelial effects: upregulates eNOS expression and nitric oxide production in vascular endothelial cells, improving vasodilation capacity
Smooth muscle effects: reduces vascular smooth muscle hypertrophy and inflammatory gene expression in aged vessels
Antioxidant: the Lys-Glu-Asp sequence may scavenge reactive carbonyl species in plasma similar to carnosine-related dipeptides
Proposed anti-atherogenic: reduces LDL oxidation and endothelial adhesion molecule expression in cell culture models

Research Findings

Khavinson group studies: Ventfort administered to elderly patients with atherosclerosis showed reduced carotid intima-media thickness vs control over 6-month period
Cell culture: LKD tripeptide at 100 nM increased eNOS mRNA by 40-60% and reduced ICAM-1 expression in TNF-alpha-stimulated endothelial cells
Aged rat model: Ventfort 10-50 mcg/kg SC daily for 30 days improved endothelial-dependent vasodilation in aortic ring preparations vs untreated aged controls
Combination with Pinealon and Thymalin: longevity peptide regimens including Ventfort in elderly patients showed trends toward reduced cardiovascular events in Russian observational studies
Research quality caveat: most Ventfort studies come from the Khavinson group (St. Petersburg Institute of Bioregulation); independent replications are limited

Research Protocols

Eastern European longevity protocol: 10 mcg/kg SC injection daily for 10-day courses, 1-2 courses/year; oral tablet form also used (10 mg/day for 30 days)
Oral formulation (Vladonix): 10 mg oral tablet equivalent of vascular bioregulator; 1-2 tablets/day for 1-3 months
Research injection dose: 50-100 mcg/kg SC daily for 30 days in preclinical aging and cardiovascular models
Combined peptide protocol: often paired with Pinealon (brain), Thymalin (immune), and Cortagen (nerve) in comprehensive longevity regimens

Interactions

Other Khavinson bioregulatory peptides (Pinealon, Thymalin, Cortagen): designed to be combined for multi-organ longevity support; no adverse interactions reported
Statins/ACE inhibitors: Ventfort may provide complementary vascular benefits but no formal pharmacokinetic or pharmacodynamic interaction studies
Antioxidants (CoQ10, alpha-lipoic acid): potentially complementary cardiovascular protection

Safety Profile

Well tolerated in published studies with no reported serious adverse effects. Caution warranted: most evidence from the developing group; limited independent validation. SC injection and oral tablet forms used. Not FDA or EMA approved; used off-label in Eastern European longevity medicine.